Cargando…
The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study
AIM OF THE STUDY: Hepatocellular carcinoma (HCC) prognosis heavily depends on early diagnosis. We aimed to determine the role of serum urothelial carcinoma-associated 1 (UCA1) and wd repeat containing antisense to TP53 (WRAP53) as diagnostic tools of HCC. MATERIAL AND METHODS: A case-control study i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369654/ https://www.ncbi.nlm.nih.gov/pubmed/37502440 http://dx.doi.org/10.5114/ceh.2023.127569 |
_version_ | 1785077803913314304 |
---|---|
author | Abdelmoety, Amr Aly Elhassafy, Mohamed Youssef Said, Rasha Said Omar Elsheaita, Ahmed Mahmoud, Manal Mohamed |
author_facet | Abdelmoety, Amr Aly Elhassafy, Mohamed Youssef Said, Rasha Said Omar Elsheaita, Ahmed Mahmoud, Manal Mohamed |
author_sort | Abdelmoety, Amr Aly |
collection | PubMed |
description | AIM OF THE STUDY: Hepatocellular carcinoma (HCC) prognosis heavily depends on early diagnosis. We aimed to determine the role of serum urothelial carcinoma-associated 1 (UCA1) and wd repeat containing antisense to TP53 (WRAP53) as diagnostic tools of HCC. MATERIAL AND METHODS: A case-control study including 90 subjects (30 patients having HCC, 30 patients having liver cirrhosis without HCC and 30 healthy controls) was performed. In all participants, the serum levels of UCA1 and WRAP53 were assessed by quantitative real-time polymerase chain reaction together with serumαa-fetoprotein (AFP). RESULTS: Serum levels of both UCA1 and WRAP53 were upregulated in patients with HCC being significantly higher than in patients with liver cirrhosis and healthy control (p < 0.001). They were also correlated with some clinicopathological characteristics of HCC. Using the receiver operating curve, both UCA1 and WRAP53 showed higher diagnostic performance for HCC (AUC = 0.9, 73.3% sensitivity, 100% specificity and AUC = 0.85, 63.3% sensitivity, 80% specificity respectively) and their combination with AFP resulted in improved sensitivity and specificity (AUC = 0.97, 90% sensitivity, 100% specificity). CONCLUSIONS: Serum UCA1 and WRAP53 have the potential to be used alone, or in combination or with AFP, as diagnostic non-invasive biomarkers for HCC with accepted sensitivity and specificity. This study has been registered in clinicaltrials.gov with clinical trial registration number NCT05088811. |
format | Online Article Text |
id | pubmed-10369654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-103696542023-07-27 The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study Abdelmoety, Amr Aly Elhassafy, Mohamed Youssef Said, Rasha Said Omar Elsheaita, Ahmed Mahmoud, Manal Mohamed Clin Exp Hepatol Original Paper AIM OF THE STUDY: Hepatocellular carcinoma (HCC) prognosis heavily depends on early diagnosis. We aimed to determine the role of serum urothelial carcinoma-associated 1 (UCA1) and wd repeat containing antisense to TP53 (WRAP53) as diagnostic tools of HCC. MATERIAL AND METHODS: A case-control study including 90 subjects (30 patients having HCC, 30 patients having liver cirrhosis without HCC and 30 healthy controls) was performed. In all participants, the serum levels of UCA1 and WRAP53 were assessed by quantitative real-time polymerase chain reaction together with serumαa-fetoprotein (AFP). RESULTS: Serum levels of both UCA1 and WRAP53 were upregulated in patients with HCC being significantly higher than in patients with liver cirrhosis and healthy control (p < 0.001). They were also correlated with some clinicopathological characteristics of HCC. Using the receiver operating curve, both UCA1 and WRAP53 showed higher diagnostic performance for HCC (AUC = 0.9, 73.3% sensitivity, 100% specificity and AUC = 0.85, 63.3% sensitivity, 80% specificity respectively) and their combination with AFP resulted in improved sensitivity and specificity (AUC = 0.97, 90% sensitivity, 100% specificity). CONCLUSIONS: Serum UCA1 and WRAP53 have the potential to be used alone, or in combination or with AFP, as diagnostic non-invasive biomarkers for HCC with accepted sensitivity and specificity. This study has been registered in clinicaltrials.gov with clinical trial registration number NCT05088811. Termedia Publishing House 2023-06-18 2023-06 /pmc/articles/PMC10369654/ /pubmed/37502440 http://dx.doi.org/10.5114/ceh.2023.127569 Text en Copyright © 2023 Clinical and Experimental Hepatology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) ) |
spellingShingle | Original Paper Abdelmoety, Amr Aly Elhassafy, Mohamed Youssef Said, Rasha Said Omar Elsheaita, Ahmed Mahmoud, Manal Mohamed The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study |
title | The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study |
title_full | The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study |
title_fullStr | The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study |
title_full_unstemmed | The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study |
title_short | The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study |
title_sort | role of uca1 and wrap53 in diagnosis of hepatocellular carcinoma: a single-center case-control study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369654/ https://www.ncbi.nlm.nih.gov/pubmed/37502440 http://dx.doi.org/10.5114/ceh.2023.127569 |
work_keys_str_mv | AT abdelmoetyamraly theroleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy AT elhassafymohamedyoussef theroleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy AT saidrashasaidomar theroleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy AT elsheaitaahmed theroleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy AT mahmoudmanalmohamed theroleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy AT abdelmoetyamraly roleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy AT elhassafymohamedyoussef roleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy AT saidrashasaidomar roleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy AT elsheaitaahmed roleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy AT mahmoudmanalmohamed roleofuca1andwrap53indiagnosisofhepatocellularcarcinomaasinglecentercasecontrolstudy |